Medical devices, healthcare technology and the business of care
PMA approval · P200002

EPi-Sense Guided Coagulation System

AtriCure, Inc. · Decision date Apr 28, 2021

MEDTECHLEDGER EXPLANATIONP200002

What did the FDA approve?

The FDA database entry for P200002 records an approval decision dated April 28, 2021, for the EPi-Sense Guided Coagulation System from AtriCure, Inc. The stated scope covers treatment of symptomatic long-standing persistent atrial fibrillation, defined as continuous atrial fibrillation lasting more than 12 months, when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use.

The patient population described in the statement is limited to people who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug, and for whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure, such as delayed post-procedure inflammatory pericardial effusions. The entry does not provide clinical outcome data or independent evidence of safety or effectiveness.

FDA approval order statement

Approval for the EPi-Sense Guided Coagulation System is intended for the treatment of symptomatic long-standing persistent atrial fibrillation (continuous atrial fibrillation greater than 12 months duration) when augmented in a hybrid procedure with an endocardial catheter listed in the instructions for use, in patients who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD); and, in whom the expected benefit from rhythm control outweighs the potential known risks associated with a hybrid procedure such as delayed post-procedure inflammatory pericardial effusions.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 28, 2021

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P200002
Regulatory pathway
Premarket approval application
Product code
OCM
Decision code
APPR
Decision date
Apr 28, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Surgical cardiac ablation device, for treatment of atrial fibrillation.

Product code
OCM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200002 received

    Application receipt date recorded by FDA.

  2. P200002 · FDA decision

    APPR

  3. P200002/S015 · Related supplement

    EPi- Sense ST Coagulation System

Timeline entries are records held by MedtechLedger for P200002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200002

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA

Explore the linked device profile

Other records with product code OCM

Product / regulatory recordCompanyPathwayDecision dateSource
AtriCure, Inc.PMA supplementSep 24, 2026FDA
AtriCure, Inc.PMA approvalDec 14, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

AtriCure, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7555 Innovation Way, Mason, OH, 45040

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records